Astera Labs (NASDAQ:ALAB) Trading Up 4.9% - Here's What Happened

Key Points

• Astera Labs (NASDAQ: ALAB) saw its stock price increase by 4.9% to $185.30, with a significant trading volume of approximately 2.4 million shares, marking a 51% decline from its average volume.
• Analysts have upgraded their ratings and price targets significantly, with Barclays setting a new price objective of $155.00 and a consensus target of $142.00 across multiple firms.
• The company reported a 149.5% year-over-year increase in quarterly revenue, achieving $191.93 million, and an EPS of $0.44, exceeding expectations by $0.11.

Astera Labs, Inc. (NASDAQ:ALAB - Get Free Report) was up 4.9% during mid-day trading on Thursday . The stock traded as high as $184.00 and last traded at $185.30. Approximately 2,403,817 shares were traded during trading, a decline of 51% from the average daily volume of 4,907,777 shares. The stock had previously closed at $176.61.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on ALAB shares. Barclays reissued an "overweight" rating and set a $155.00 price objective (up from $75.00) on shares of Astera Labs in a research note on Thursday, August 7th. Susquehanna upped their price target on shares of Astera Labs from $80.00 to $125.00 and gave the stock a "neutral" rating in a research report on Thursday, August 7th. Zacks Research raised shares of Astera Labs to a "strong-buy" rating in a research report on Tuesday, August 12th. Jefferies Financial Group upped their price target on shares of Astera Labs from $95.00 to $130.00 and gave the stock a "buy" rating in a research report on Tuesday, July 22nd. Finally, Needham & Company LLC upped their price target on shares of Astera Labs from $100.00 to $170.00 and gave the stock a "buy" rating in a research report on Wednesday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and three have given a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $142.00.

Astera Labs Price Performance

The firm's fifty day moving average is $137.83 and its 200-day moving average is $97.51. The stock has a market capitalization of $31.24 billion, a price-to-earnings ratio of 335.63, a PEG ratio of 4.62 and a beta of 1.48.

Astera Labs (NASDAQ:ALAB - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $0.44 EPS for the quarter, topping analysts' consensus estimates of $0.33 by $0.11. Astera Labs had a return on equity of 9.53% and a net margin of 16.54%.The business had revenue of $191.93 million during the quarter, compared to the consensus estimate of $172.46 million. During the same period last year, the firm earned $0.13 earnings per share. The company's revenue for the quarter was up 149.5% compared to the same quarter last year. Astera Labs has set its Q3 2025 guidance at 0.380-0.390 EPS. On average, sell-side analysts expect that Astera Labs, Inc. will post 0.34 EPS for the current year.

Insider Transactions at Astera Labs

In related news, CEO Jitendra Mohan sold 152,517 shares of the stock in a transaction dated Thursday, August 7th. The shares were sold at an average price of $170.33, for a total transaction of $25,978,220.61. Following the sale, the chief executive officer owned 450,001 shares in the company, valued at $76,648,670.33. This represents a 25.31% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Michael Truett Tate sold 100,000 shares of the stock in a transaction dated Thursday, August 7th. The stock was sold at an average price of $171.38, for a total transaction of $17,138,000.00. Following the sale, the chief financial officer owned 518,996 shares in the company, valued at approximately $88,945,534.48. This trade represents a 16.16% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 1,649,489 shares of company stock worth $232,463,986. 12.50% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Astera Labs

Several institutional investors and hedge funds have recently bought and sold shares of the business. Oliver Lagore Vanvalin Investment Group bought a new stake in shares of Astera Labs during the second quarter valued at about $29,000. Bernard Wealth Management Corp. acquired a new position in Astera Labs in the 2nd quarter worth approximately $36,000. Clearstead Trust LLC raised its position in Astera Labs by 46,100.0% during the second quarter. Clearstead Trust LLC now owns 462 shares of the company's stock valued at $42,000 after buying an additional 461 shares during the period. Advisors Asset Management Inc. lifted its position in shares of Astera Labs by 68.6% in the second quarter. Advisors Asset Management Inc. now owns 477 shares of the company's stock worth $43,000 after purchasing an additional 194 shares in the last quarter. Finally, Manchester Capital Management LLC lifted its position in Astera Labs by 141.5% in the 2nd quarter. Manchester Capital Management LLC now owns 483 shares of the company's stock worth $44,000 after buying an additional 283 shares in the last quarter. Institutional investors and hedge funds own 60.47% of the company's stock.

Astera Labs Company Profile

Astera Labs, Inc designs, manufactures, and sells semiconductor-based connectivity solutions for cloud and AI infrastructure. Its Intelligent Connectivity Platform is comprised of a portfolio of data, network, and memory connectivity products, which are built on a unifying software-defined architecture that enables customers to deploy and operate high performance cloud and AI infrastructure at scale.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.